Genital Vitiligo-like Hypopigmentation After Treatment With 5% Imiquimod

García-Montero, P.; Jiménez, J.B. Repiso; Morano, M; Troya-Martín, Magdalena de

doi:10.1016/j.adengl.2017.03.011

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, only approximately 30 cases have been reported. Imiquimod-induced vitiligo and vitiligo-like hypopigmentation/depigmentation have been reported to occur subsequent to topical treatment for genital warts (condyloma acuminatum) [ 28 – 38 ], BCC [ 39 – 43 ], periungual verruca vulgaris [ 44 ], extramammary Paget's disease [ 45 ], melanoma or metastatic melanoma [ 24 , 46 ], AK [ 47 ], and radiation keratosis [ 48 ]. Only one case of pigment loss during or after the treatment of AK has been reported [ 47 ], as the frequency of treatment for AK is twice a week according to the FDA-indicated regimen, which is lower than the frequency of treatment for BCC (five times a week for 6 weeks) and genital warts (3 times a week for a maximum of 16 weeks) [ 49 ].…”

Section: Rare Imiquimod-associated Cutaneous Side Effectsmentioning

confidence: 99%

Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management

Zhang

Xie

Wang

2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

As an immune-response modifier, imiquimod can bind to Toll-like receptors on immune cells and enhance innate and adaptive immune responses, exerting potential antitumor and antiviral effects, which led to its approval by the US Food and Drug Administration for the treatment of actinic keratosis, superficial basal cell carcinomas, and anogenital warts, and to its off-label use in treating many other benign and malignant dermatoses. Although topical administration of imiquimod has been considered well tolerated, an increasing number of cutaneous and noncutaneous side effects are being reported as its clinical applications expand. This review primarily focuses on rare cutaneous side effects. To the best of our knowledge, this is the first article to summarize the mechanism, diagnosis, and management of rare cutaneous side effects of imiquimod, which may help to heighten awareness among physicians, especially dermatologists, about potential imiquimod-induced cutaneous side effects.

show abstract